Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
Conditions
Interventions
BIIB104
Placebo
Locations
60
United States
Pillar Clinical Research, LLC
Bentonville, Arkansas, United States
ProScience Research Group
Culver City, California, United States
Collaborative Neuroscience Network, LLC
Garden Grove, California, United States
Synergy San Diego
Lemon Grove, California, United States
Research Site
Long Beach, California, United States
Catalina Research Institute, LLC
Montclair, California, United States
Start Date
November 15, 2018
Primary Completion Date
March 23, 2022
Completion Date
April 7, 2022
Last Updated
April 18, 2023
NCT07446478
NCT05686239
NCT05136690
Lead Sponsor
Biogen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions